Find Academic Supervisors

• Computational Genomics
• Maternal-Fetal Medicine
• Placental Biology
• +3 more

Kathleen Fisch, PhD is an Assistant Professor at the University of California, San Diego School of Medicine, Department of Obstetrics, Gynecology and Reproductive Sciences. She serves as Faculty Director of the Center for Computational Biology & Bioinformatics (CCBB) and Co-Director of the ACTRI Center for Excellence in Translational Immunogenomics (CETI), leading initiatives in computational genomics and bioinformatics infrastructure. University of California, Berkeley: B.A. in Integrative Biology University of California, Davis: Ph.D. in Ecology (Population Genetics) Her research focuses on genomic and computational approaches to maternal-fetal medicine, placental biology, and translational immunogenomics. This includes studies on preeclampsia, HPV-mediated cancers, and SARS-CoV-2 placental transmission using multi-omics and systems biology frameworks. Key publication trends include: Genomic analysis of placental lesions in preeclampsia Single-cell transcriptomics in reproductive tissues Computational modeling of pain signatures and opioid addiction HPV extrachromosomal DNA in oropharyngeal cancer Epigenetic regulation in viral infections and autoimmune conditions Dr. Fisch collaborates on NIH-funded projects including R21HD110893 (Placental Lesions in Preeclampsia), U54HD110347 (Pregnant Female Reproductive Tissue Mapping), and U54DA049115 (Acute to Chronic Pain Signatures Program).

Niall BarronView profile

Professor

• Biomedical Engineering
• Biochemical Engineering
• Cellular and Molecular Biology
• +5 more

Professor Niall Barron is a Professor of Biochemical Engineering at the School of Chemical and Bioprocess Engineering, University College Dublin (UCD), and a Principal Investigator at the National Institute for Bioprocessing Research and Training (NIBRT). He holds a BA (Mod) in Microbiology from Trinity College Dublin and a PhD in Applied Microbiology/Biochemistry from the University of Ulster (1997). His postdoctoral research at Baylor College of Medicine focused on nuclear steroid receptor function via genome engineering. He has held academic and research roles at Dublin City University (DCU), including Director of the National Institute for Cellular Biotechnology (NICB) from 2015–2017. His research focuses on genetic engineering strategies to improve recombinant protein production in CHO cells, AAV/LV vector manufacturing, and epigenetic regulation of bioprocess performance. He leads projects funded by industry and EU grants, including initiatives to enhance gene therapy vector production and mRNA methylation control. Education: BA (Mod) in Microbiology, Trinity College Dublin PhD in Applied Microbiology/Biochemistry, University of Ulster (1997) Research Interests: Targeted genome editing in CHO cells for improved biopharmaceutical production Optimization of AAV and LV vector systems for gene therapy miRNA and epitranscriptomic regulation of cellular processes Single-cell analysis to understand clonal variability and production instability Grants & Collaborations: Lead on grants from GSK, Enterprise Ireland, and Horizon 2020 (e.g., STACCATO, GeneClick) Focus on advancing bioprocess technologies and cell line engineering Teaching: Coordinates modules in biopharmaceutical manufacturing, biotechnology principles, and gene therapy processes Program Director for the MEngSc in Biopharmaceutical Manufacturing (Part-Time) Labs & Teams: Leads a multidisciplinary team at UCD and NIBRT focusing on biopharmaceutical engineering and cell line optimization

• Molecular Genetics
• Epigenetics
• Cancer Biology
• +5 more

Carol IMBRIANO is an Associate Professor at the University of Modena and Reggio Emilia, Department of Life Sciences ex-Biology. She specializes in molecular genetics, epigenetics, and their applications in cancer biology and medical biotechnology. Her research focuses on transcription factors like NF-Y, particularly their roles in tumor progression, metabolic reprogramming, and epigenetic regulation. She also develops biosensor technologies using organic electrochemical transistors for DNA detection. Her teaching responsibilities include courses on molecular genetics and epigenetics for biosciences, genetics laboratory work for biotechnology students, and personalized therapy modules in medical biotechnology. These courses integrate theoretical and practical components, such as bioinformatics analysis and lab safety protocols. She emphasizes critical thinking and data interpretation through written and oral exams, often using international scientific literature. Research interests revolve around the molecular mechanisms underlying cancer aggressiveness, including NF-Y splicing dynamics in metastasis, estrogen receptor interactions in prostate cancer, and sigma-2 receptor targeting for melanoma therapy. She explores how epigenetic modifications (e.g., DNA methylation, histone variants) contribute to disease development and leverages nanomedicine for therapeutic delivery and diagnostic innovation. Her work bridges basic science with clinical applications in precision medicine and cancer stratification. Publications consistently highlight advanced topics in transcription factor biology, cancer metabolism, and nanosensor development. She collaborates with multidisciplinary teams on projects like EGOT biosensors and drug discovery for CRPC. Despite her extensive contributions, no scientific awards or grants are explicitly listed in the provided texts. She maintains an open-door policy for students via prior arrangement and uses digital platforms like Teams for course materials.

• Hematopoiesis
• Myelopoiesis
• RNA Modifications
• +12 more

Dr. Stephanie Halene is the Arthur H and Isabel Bunker Professor of Medicine (Hematology) and Professor of Pathology at Yale School of Medicine. She serves as Chief of Hematology at Yale Cancer Center and Smilow Cancer Hospital, Assistant Medical Director of CRSL at Yale Cancer Center, and Director of the DeLuca Center for Innovation in Hematology Research. Dr. Halene received her MD from Eberhard-Karls-University in Tübingen, Germany. Her training includes a postdoctoral fellowship with Donald B. Kohn at Children's Hospital Los Angeles, residency in internal medicine at Yale New Haven Hospital, and fellowship in hematology/oncology at Yale. She joined the Yale School of Medicine faculty as an assistant professor in 2010, was promoted to associate professor in 2016, and became Chief of the Section of Hematology in 2020. Dr. Halene's research focuses on hematopoiesis and myelopoiesis, particularly how mutations in splicing factors and RNA modifications contribute to hematologic malignancies such as myelodysplasia and leukemia. Her laboratory has developed the first efficient xenotransplantation model in humanized mice to study myelodysplasia. Her work spans molecular biology, RNA biology, and translational hematology, with applications to understanding and treating blood disorders. Dr. Halene's publications demonstrate a strong focus on RNA modifications, splicing factor mutations, and their roles in hematologic malignancies. Her research integrates cutting-edge technologies including single-cell analysis, xenotransplantation models, and multi-omic approaches to unravel disease mechanisms and develop novel therapeutics. Elected Member, Connecticut Academy of Science and Engineering (2024) Recipient of the "2nd Century of Women: Emerging Leaders in Internal Medicine" Award (2022) Elected Member, Interurban Clinical Club (2019) Sir William Osler Young Investigator Award (2015) Career Development Award, Yale School of Medicine (2010) As Director of the DeLuca Center for Innovation in Hematology Research, Dr. Halene oversees a comprehensive biospecimen bank and administers pilot and career development grants to advance discoveries in hematologic malignancies. She also co-directs the Mouse Modeling Core of the Yale Cooperative Center of Excellence in Hematology, providing researchers with access to the latest technologies for hematologic studies in animal models. Dr. Halene leads the Halene Laboratory, which focuses on myeloid malignancies and hematopoiesis. The lab maintains the Hematology Tissue Bank, providing researchers access to critical patient samples for studying hematologic diseases. She also serves on the External Advisory Board for the Cellular & Molecular Biology Masters Program and is actively involved in clinical care, focusing on both malignant and classical hematologic disorders.

Charles E. SamuelView profile

Research Professor

• Virology
• Interferon Biology
• RNA Editing
• +6 more

Charles E. Samuel is a Research Professor and Distinguished Professor Emeritus at the University of California, Santa Barbara (UCSB). He holds the C.A. Storke II Professorship and has served in leadership roles, including Director of the Biochemistry & Molecular Biology Program (1987-95) and Chair of the Department of Molecular, Cellular & Developmental Biology (MCDB) (1995-98 and 2001-04). He earned his B.S. in Chemistry from Montana State University and his Ph.D. in Biochemistry from UC Berkeley. His research focuses on interferon-mediated antiviral mechanisms, RNA editing enzymes (ADAR1/PKR), and virus-host interactions. He is an associate editor of the Journal of Biological Chemistry and Journal of Interferon & Cytokine Research . Education: B.S., Chemistry, Montana State University Ph.D., Biochemistry, UC Berkeley Research interests include: Mechanisms of interferon action RNA editing and innate immunity PKR and ADAR enzymes in viral pathogenesis Measles virus replication and stress responses Key awards: NIH MERIT Award Humboldt Forschungspreis Fellowships: AAAS and American Academy of Microbiology Advising: Supervised over 40 graduate students and postdoctoral fellows. Grants include NIH-funded projects on interferon biology and antiviral mechanisms. His lab investigates viral factories, stress granules, and gene delivery systems using cationic liposomes.

Jörg MeurerView profile

Research Professor

• Plastid RNA Metabolism
• Photosynthetic Complex Assembly
• Chloroplast Biogenesis
• +3 more

PD Dr. Jörg Meurer is a Research Professor and Staff Scientist at the Department of Plant Sciences, Faculty of Biology, Ludwig-Maximilians-University Munich (LMU). His research focuses on plastid RNA metabolism and assembly of photosynthetic complexes, with expertise in chloroplast gene expression regulation and proteomics. He holds a Diploma in Botany from Heinrich-Heine University Düsseldorf (1992), completed his PhD in Botany (1996) and Habilitation (2005) at LMU Munich. Professional highlights include postdoctoral fellowships at Friedrich-Schiller University Jena and the Max Planck Institute for Plant Breeding Research. Since 1999, he has led projects at LMU’s Plant Sciences section, organizing the Proteomics Service since 2013. His teaching encompasses Bachelor/Master courses in plant biology. He also serves as Radiation Protection Commissioner and Safety Officer. Research contributions span chloroplast RNA stability, photosystem assembly, and stress responses, with over 150 publications in peer-reviewed journals. Education: 1986-1992: Diploma in Botany, Heinrich-Heine University Düsseldorf 1992-1996: PhD (Dr. rer. nat.) in Botany, supervised by Prof. Peter Westhoff 2005: Habilitation in Botany, LMU Munich Research Interests: Plastid RNA metabolism and regulation Photosynthetic complex assembly mechanisms Chloroplast biogenesis and stress responses Proteomics of chloroplast components Recent Article Trends: Focus on chloroplast epitranscriptomics, thylakoid protein dynamics, and stress response mechanisms. Recent work explores RNA editing via designer proteins, ubiquitin-mediated protein interactions, and nucleotide metabolism impacts on photosynthesis. Lab Activities: Leads the Proteomics Service at LMU Biocenter, providing cutting-edge proteomic analysis for plant research. Collaborates in the Green Hub consortium studying plant acclimation mechanisms.

Zhang XiurenView profile

Professor

• RNA silencing
• RNA structure and remodeling
• ribonucleoprotein complexes
• +5 more

Zi Zhang Xiuren is the Christine Richardson Endowed Professor of Agricultural Biology and holds the rank of Professor in the Department of Biochemistry & Biophysics at Texas A&M University's College of Agriculture & Life Sciences. He is also an EDGES Fellow, Presidential Impact Fellow, and AgriLife Faculty Fellow. His research focuses on RNA silencing pathways, RNA structure remodeling, and host-virus interactions in plants. He employs genetic, molecular, and biochemical approaches to study miRNA and siRNA-mediated regulation, epigenetic mechanisms, and viral defense strategies. Key contributions include identifying components of RNA silencing pathways and elucidating the roles of RNA structure and epigenetic modifications in plant development and immunity. Education: B.S. from Hefei College of Economy and Technology (1989), Ph.D. in Molecular Genetics from Cornell University (2003), and postdoctoral training at Rockefeller University (2008). Research Interests: RNA silencing mechanisms and their roles in plant growth and antiviral defense RNA secondary structure (RSS) and epi-modifications (REM) in gene expression regulation Host-virus interactions, particularly with Geminivirus and Cucumber Mosaic Virus Epigenetic suppression by viral proteins like TrAP Awards & Fellowships: Christine Richardson Endowed Professorship Presidential Impact Fellow EDGES Fellow AgriLife Faculty Fellow Grants & Advising: Active in securing research grants and mentoring students in molecular genetics and plant biology. His lab collaborates on projects involving miRNA biogenesis, viral suppression mechanisms, and epigenetic regulation. Labs & Teams: Leads a research group focused on RNA biology at Texas A&M, contributing to initiatives like the Texas A&M AgriLife Research program.

Yang Yun-GuiView profile

Professor

• DNA repair
• RNA methylation
• Epitranscriptomics
• +2 more

Yang Yun-Gui is a Professor at the Beijing Institute of Genomics, Chinese Academy of Sciences (CAS), holding this position since November 2008. He concurrently serves as Assistant Director of the Beijing Institute of Genomics since December 2019 and Head of the Education Program for Life Science Engineering and Informatics at the Sino-Danish College, CAS since January 2015. His academic foundation includes a B.Sc in Microbiology from Fudan University (1995) and a Ph.D. in Biochemistry and Molecular Biology from the Shanghai Institute of Materia Medica, CAS (2000). He completed extensive postdoctoral training at the International Agency for Research on Cancer in Lyon, France (2000-2005) and Clare Hall Laboratories in London under Nobel Laureate Tomas Lindahl (2005-2008). Dr. Yang's research spans DNA repair mechanisms, RNA methylation dynamics, epitranscriptomics, cancer biology, and chemical biology. He pioneered discoveries on DNA repair proteins (NBS1/FANCA/PARP1) and identified Trex1 exonuclease's critical role in degrading ssDNA to prevent innate immune activation. His current work focuses on mapping epitranscriptomic RNA modifications, particularly dynamic RNA methylation patterns in disease contexts. His accolades include: 2019 Jiazhen Tan Life Science Innovation Award Consecutive Excellent Supervisor Awards (2018, 2019) State Council Special Government Allowance (2018) National "Millions Talent Plan" Award (2017) Top 10 Life Science Advances of China (2017) National Science Fund for Distinguished Young Scholars (2016) "100-Talents" Program Excellence Award (2014) As an educator, he received the Zhu Li Yuehua Outstanding Teacher Award (2013) and CAS-BHPB Mentor Research Award (2012). His research is funded by elite programs including the National Science Fund for Distinguished Young Scholars and Millions Talent Plan. Dr. Yang leads advisory roles in national funding agencies and academic societies while directing research initiatives at the Beijing Institute of Genomics focused on RNA modification therapeutics.

Beverly E. ShaView profile

Professor

• Infectious Diseases
• HIV/AIDS Research
• Clinical Medicine
• +3 more

Beverly E. Sha, MD is a Professor in the Department of Internal Medicine, Division of Infectious Diseases at Rush Medical College, Rush University. She serves as Director of the Mark Weiss Memorial Clinic for Infectious Diseases. Her academic roles include clinical care, research, and teaching in infectious diseases. Dr. Sha completed her medical degree at Johns Hopkins University School of Medicine, followed by residency and fellowship in Internal Medicine and Infectious Diseases at Rush University Medical Center. Her research focuses on HIV/AIDS pathogenesis, cardiovascular comorbidities in HIV patients, and infectious disease epidemiology. She contributes to clinical trials evaluating therapies for HIV-associated cardiovascular risk and SARS-CoV-2 transmission dynamics. Dr. Sha has also published on adult immunization strategies and vaccination optimization in immunocompromised populations. Her clinical expertise spans complex infectious disease management, with particular emphasis on HIV and viral infections. Patient reviews highlight her attentive care and clear communication. She maintains affiliations with multiple healthcare organizations and participates in professional networks.

Arne KlunglandView profile

Professor

• Epigenetics
• Epitranscriptomics
• DNA Repair
• +7 more

Arne Klungland is a Professor and Centre Director at the Centre for Embryology and Healthy Development (CRESCO), affiliated with the University of Oslo and Oslo University Hospital. His research spans molecular biology, epigenetics, DNA repair, and embryology, with a focus on RNA modifications such as m6A and m1A methylation. University: University of Oslo School: Faculty of Medicine Department: Centre for Embryology and Healthy Development (CRESCO) Academic Rank: Professor Email: arne.klungland@medisin.uio.no His research interests include epigenetics, epitranscriptomics, DNA repair, meiosis, and embryology. His work investigates how RNA modifications regulate gene expression during development and disease, particularly in gametogenesis, stem cell biology, and cancer. He has made significant contributions to understanding m6A and m1A dynamics in mammalian systems. The recent articles highlight a strong trend in RNA epigenetics, particularly m6A and m1A modifications in embryonic development, stem cells, and cancer. His research integrates high-throughput sequencing, molecular biology, and functional genomics to explore post-transcriptional regulation in development and disease. Scientific awards are not mentioned in the provided text. Klungland leads a dynamic research group at CRESCO, mentoring students and postdoctoral researchers. He has been involved in numerous collaborative research projects on DNA repair, RNA modifications, and developmental biology. His lab utilizes advanced techniques such as single-cell RNA mapping, ChIP, and functional assays in mouse and human models. While specific grant details are not listed, his consistent publication in top journals indicates sustained funding and research activity. He leads the Centre for Embryology and Healthy Development (CRESCO), a multidisciplinary research center focused on understanding molecular mechanisms of embryogenesis, fertility, and developmental disorders. The center fosters collaboration between basic scientists and clinicians to translate findings into improved reproductive health outcomes.

Amedeo CaflischView profile

Professor

• Computational Structural Biology
• Epigenetics
• Epitranscriptomics
• +3 more

Amedeo Caflisch is a Full Professor of Computational Structural Biology at the University of Zurich's Department of Biochemistry since 2001. He previously served as Head of the Department from 2020 to 2024. His research focuses on developing small molecule ligands targeting proteins involved in epitranscriptomics (e.g., m6A-RNA writers/readers) and epigenetics (acetylated lysine readers), aiming to create anti-cancer therapies. He earned a Ph.D. in Theoretical Physics from ETH Zurich in 1991, followed by postdoctoral work at Harvard University with Prof. Martin Karplus. He joined the University of Zurich in 1995 as a senior research assistant and became an assistant professor in 1996. Teaching includes courses such as 'Protein Biophysics' and 'Biochemistry: An Overview' within the Faculty of Science. His lab, the Caflisch Group, investigates molecular dynamics, drug design, and protein aggregation mechanisms. Key projects involve computational methods for virtual screening and understanding amyloid formation in diseases like Alzheimer's. Collaborations span medicinal chemistry, structural biology, and pharmacology, with a focus on translating computational insights into clinical applications. Career highlights include pioneering work on epigenetic modifiers and the development of FAIR-compliant data management tools for molecular simulations. His lab's interdisciplinary approach combines AI, physics-based models, and experimental validation to address complex biological problems.

James D. BrooksView profile

Professor

• Urologic Oncology
• Prostate Cancer Biomarkers
• Kidney Cancer Research
• +5 more

James D. Brooks is the Keith and Jan Hurlbut Professor of Urology at Stanford University School of Medicine. He holds academic appointments in Urology, Bio-X Institute, Maternal & Child Health Research Institute, and Stanford Cancer Institute. His administrative roles include Director of the U54 Stanford O’Brien Urology Research Center and Vice Chair of the Department of Urology. Dr. Brooks’ research focuses on biomarker discovery for urological diseases, particularly prostate and kidney cancers. His work spans genomic/proteomic methods, clinical trials for biomarker validation, and collaborations in molecular imaging. He leads initiatives like the Canary Prostate Active Surveillance Study (PASS) and has pioneered studies on prostate cancer aggressiveness classification using AI. His clinical expertise includes urologic oncology, prostate cancer screening, and management of localized prostate cancer. He has authored over 430 publications and received prestigious awards including the Clinician Scientist Award from the Doris Duke Foundation and the Best Doctors in America recognition. Dr. Brooks’ educational background includes an A.B. in Biology from the University of Chicago and an MD from Stanford University School of Medicine. He completed residencies at Johns Hopkins University and holds board certifications in Urology.

• Alzheimer's Disease
• Neurodegeneration
• Neural Stem Cells
• +4 more

Caghan Kizil, PhD, is an Associate Professor of Neurological Sciences at Columbia University, affiliated with the Taub Institute and Neurology department. He leads research on Alzheimer’s disease (AD) neurodegeneration mechanisms, focusing on neural regeneration, stem cell plasticity, and translational therapies using zebrafish models. Education: BSc, 2003 – Middle East Technical University, Turkey MSc, 2005 – Max Planck Institute for Biophysical Chemistry, Germany PhD, 2009 – Max Planck Institute for Developmental Biology, Germany Research Interests: His lab integrates multi-omics approaches, gene editing, and in vitro models to uncover AD pathogenesis and identify therapeutic targets. Key areas include neurogenesis enhancement, blood-brain barrier dysfunction, and epigenetic regulation of tau phosphorylation. Awards: 2021 Schaefer Research Scholar Award (Columbia University) 2013 Helmholtz Association Young Investigator Award 2005 Max Planck Society fellowship Labs & Collaborations: The Kizil Lab (kizillab.org) develops chemical screening platforms and leverages clinical data-driven models to advance AD drug discovery.

Boxuan ZhaoView profile

Assistant Professor

• Neuroscience
• Neurologic disorders
• RNA Biology
• +8 more

Boxuan Zhao is an Assistant Professor of Cell and Developmental Biology and the Neuroscience Program at the University of Illinois Urbana-Champaign, with an affiliate role at the Carl R. Woese Institute for Genomic Biology. His research focuses on RNA biology, epigenetics, and neurobiology, developing cutting-edge technologies to map brain connectivity and molecular mechanisms underlying neural function. He holds a B.S. from Peking University (2012), M.S./Ph.D. from the University of Chicago (2017), and completed postdoctoral training at Stanford University (2017-2023). Research interests include RNA modifications (e.g., m6A), single-cell multi-omics, and systems-level analysis of brain organization. His lab integrates transcriptomics, proteomics, and connectomics to study neuronal connectivity dynamics and molecular mechanisms of brain disorders. Key contributions include methods like Connectome-seq for high-resolution neuronal mapping and RNA-protein interaction mapping via APEX targeting. Highlighted Achievements: 2023 & 2022 Web of Science Highly Cited Researcher in Molecular Biology Howard Hughes Medical Institute Predoctoral Fellowship (2014) Winner of multiple innovation awards in RNA biology and chemical biology Publications span foundational insights into m6A’s role in mRNA translation, viral replication, and developmental transitions. Zhao’s interdisciplinary approach bridges chemical biology, neuroscience, and genomics, with a focus on translational applications in health and disease.

• Molecular Cancer Biology
• Melanoma Metastasis
• Immunotherapy Resistance
• +7 more

Jean-Christophe Marine is a full professor at the KU Leuven Faculty of Medicine , leading the Laboratory for Molecular Cancer Biology (VIB-KU Leuven). His work focuses on unraveling molecular mechanisms in melanoma and pancreatic cancer, with a particular emphasis on metastasis, immunotherapy resistance, and tumor microenvironment dynamics. Head, Laboratory for Molecular Cancer Biology (VIB-KU Leuven) Head, VIB-KU Leuven Center for Cancer Biology - Administrative Core Member, VIB-KU Leuven Center for Cancer Biology Member, LISCO - KU Leuven Institute for Single Cell Omics Senior academic staff, Faculty of Medicine Council His research spans cell state plasticity , lipid metabolism in metastasis , epitranscriptomic regulation , and novel spatial analysis technologies . Recent projects include studying extracellular vesicles in pre-metastatic niche formation and developing AI-driven pipelines for cancer cell mapping. Publications highlight discoveries in NK cell-mediated immunotherapy resistance , alternative translation in metastasis , and oncofetal reprogramming in colorectal cancer. Collaborative work includes defining stromal lipid species as metastatic drivers and mapping melanoma subclone plasticity using single-cell multi-omics. Current affiliations include leadership roles in cancer biology centers and advisory positions in institutional councils. His work intersects basic research and clinical translation , with major implications for precision oncology.